title: [eIF3a gene polymorphism and chemo-sensitivity to platinum-based drugs in ovarian cancer].
abstract: OBJECTIVE
  To investigate the relationship between the eukaryotic initiation factor 3a (eIF3a)polymorphisms and chemo-sensitivity to platinum-based drug in ovarian cancer.
  
  
  METHODS
  Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis was performed to detect 57 cases of eIF3a polymorphic genotypes (rs3824830, rs77382849, rs10787899 and rs3740556) after platinum-based chemotherapy drugs up to 6 cycles in primary ovarian cancer. The association between these gene sites was analyzed.
  
  
  RESULTS
  There were 3 genotypes for eIF3a rs3824830, named AA, GA and GG. The frequency distribution for them was 43.86%, 36.84% and 15.79% (2 cases did not detect the genotype, 3.51%), respectively. There were 2 genotypes for eIF3a rs77382849, named CC and TC. The frequency distribution for them was 85.96% and 12.28%(1 case did not detect the genotype, 1.76%), respectively. There were 3 genotypes for eIF3a rs10787899, named GG, GA and AA, respectively. The frequency distribution for them was 26.32%, 47.36% and 26.32%, respectively. There were significant difference in different genotypes between age group and FIGO stage (P<0.05). The genotype of eIF3a rs10787899 GA was easier to resist platinum drug compared with the GG genotype and the odds ratio could be increased by 2.676 (95%CI: 0.544-13.159). The genotype of eIF3a rs10787899 AA was easier to resist platinum drug compared with the GG genotype and the odds ratio could be increased by 5.419(95%CI: 0.964-30.471). Rebalanced by age and FIGO stage, there was no significant difference (P>0.05) among these genotype groups. In all blood samples, there was only one genotype for eIF3a rs3740556, named GG.
  
  
  CONCLUSIONS
  There is no mutation genotype in eIF3a rs3740556 loci. Polymorphism in the eIF3a rs3824830, rs77382849 and rs10787899 doesn't affect the response of ovarian cancer to platinum-based chemotherapy.
authors.affiliation: Department of Gynaecology and Obstetrics,Xiangya Hospital,Central South University, Changsha 410008, China.
authors.forename: Caiyi
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Department of Gynaecology and Obstetrics,Xiangya Hospital,Central South University, Changsha 410008, China.
authors.forename: Shufen
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Institute of Clinical Pharmacology, Xiangya Hospital,  Central South University, Changsha 410008, China.
authors.forename: Yingzi
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Gynaecology and Obstetrics,Xiangya Hospital,Central South University, Changsha 410008, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Tian
authors.affiliation: Department of Gynaecology and Obstetrics,Xiangya Hospital,Central South University, Changsha 410008, China.
authors.forename: Xinguo
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Gynaecology and Obstetrics,Xiangya Hospital,Central South University, Changsha 410008, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D039621:Eukaryotic Initiation Factor-3 / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D009154:Mutation; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010984:Platinum / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D000970:Antineoplastic Agents; C105988:EIF3A protein, human; D039621:Eukaryotic Initiation Factor-3; D010984:Platinum